AR031867A1 - Compuestos derivados de fenoxibencilamina como ssri, su uso en la preparacion de medicamentos, procedimiento de preparacion del compuesto e intermediarios utiles - Google Patents
Compuestos derivados de fenoxibencilamina como ssri, su uso en la preparacion de medicamentos, procedimiento de preparacion del compuesto e intermediarios utilesInfo
- Publication number
- AR031867A1 AR031867A1 ARP010104114A ARP010104114A AR031867A1 AR 031867 A1 AR031867 A1 AR 031867A1 AR P010104114 A ARP010104114 A AR P010104114A AR P010104114 A ARP010104114 A AR P010104114A AR 031867 A1 AR031867 A1 AR 031867A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- compounds
- preparation
- heterocyclic ring
- independently substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 title abstract 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 abstract 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 101710164184 Synaptic vesicular amine transporter Proteins 0.000 abstract 1
- 102100034333 Synaptic vesicular amine transporter Human genes 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- YXMXAXHPRPWBJB-UHFFFAOYSA-N n-phenoxy-1-phenylmethanamine Chemical compound C=1C=CC=CC=1CNOC1=CC=CC=C1 YXMXAXHPRPWBJB-UHFFFAOYSA-N 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 206010036596 premature ejaculation Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000009103 reabsorption Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Quinoline Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto derivado de fenoxibencilamina de formula general (1), sus sales, solvatos o polimorfos farmacéuticamente aceptables, donde: R1 y R2, que pueden ser iguales o diferentes, son H, alquilo C1-6 o (CH2)d-cicloalquilo C3-6, donde d es 0, 1, 2 o 3; o R1 y R2 junto con el nitrogeno al que están unidos forman un anillo de azetidina; uno de Z o Y es -SR3 y el otro de Z o Y es halogeno o -R3; donde R3 es independientemente alquilo C1-4 opcionalmente sustituido con fluor; excepto que R3 no es CF3; o Z e Y están unidos de manera que, junto con los átomos de interconexion, Z e Y forman un anillo carbocíclico o heterocíclico de 5 a 7 miembros, condensado, que puede ser saturado, insaturado o aromático, y donde, cuando Z e Y forman un anillo heterocíclico, además de átomos de C, el enlace contiene uno o dos heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrogeno; con la condicion que cuando R5 es fluor y R2 es metilo, entonces el anillo condensado no es 1,3-dioxolano y Z e Y juntos no forman un anillo de fenilo condensado; R4 y R5, que pueden ser iguales o diferentes, son: A-X, donde A es -CH=CH- o -(CH2)p-, donde p es 0, 1 o 2; X es hidrogeno, F, Cl, Br, I, CONR6R7, SO2NR6R7, SO2NHC(=O)R6, OH, alcoxi C1-4, NR8SO2R9, NO2, NR6R11, CN, CO2R10, CHO, SR10, S(O)R9, o SO2R10; R6, R7, R8 y R10, que pueden ser iguales o diferentes, son hidrogeno o alquilo C1-6 opcionalmente sustituido independientemente con uno o más R12; R9 es alquilo C1-6 opcionalmente sustituido independientemente con uno o más R12, R11 es hidrogeno, alquilo C1-6 opcionalmente sustituido independientemente con uno o más R12, C(O)R6, CO2R9, C(O)NHR6 o SO2NR6R7; R12 es F, OH, CO2H, cicloalquilo C3-6, NH2, CONH2, alcoxi C1-6, alcoxi C1-6-carbonilo o un anillo heterocíclico de 5 o 6 miembros que contiene 1, 2 o 3 heteroátomos seleccionados entre N, S y O, opcionalmente sustituido independientemente con uno o más R13; o R6 y R7, junto con el nitrogeno al que están unidos, forman un anillo heterocíclico de 4, 5 o 6 miembros opcionalmente sustituido independientemente con uno o más R13; o un anillo heterocíclico de 5 o 6 miembros que contiene 1, 2 o 3 heteroátomos seleccionados entre N, S y O, opcionalmente sustituido independientemente con uno o más R13; donde R13 es hidroxi, alcoxi C1-4, F, alquilo C1-6, haloalquilo, haloalcoxi, -NH2, -NH(alquilo C1-6) o -N(alquilo C1-6)2. Compuestos de éter difenílico que inhiben la reabsorcion de monoaminas. En particular los compuestos presentan actividad como inhibidores selectivos de la reabsorcion de serotonina (SSRI, del inglés selective serotonin re-uptake inhibitors) y tienen utilidad, por tanto en diversas áreas terapéuticas. Más notablemente, los compuestos de la presente son utiles en el tratamiento o prevencion de diversos trastornos, incluidos aquellos en los que está implicada la regulacion de la funcion de los transportadores de monoaminas, tales como depresion, trastorno de hiperactividad con déficit de atencion, trastorno obsesivo compulsivo, trastorno de estrés post-traumático, trastornos de abuso de sustancias y disfuncion sexual, incluida eyaculacion precoz, y a las formulaciones farmacéuticas que contienen tales compuestos. Se describe también su uso en la preparacion de medicamentos, proceso para la preparacion de los compuestos e intermediarios utiles en su fabricacion.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0021593A GB0021593D0 (en) | 2000-08-31 | 2000-08-31 | Diphenyl ether compounds useful in therapy |
| GB0107116A GB0107116D0 (en) | 2001-03-21 | 2001-03-21 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031867A1 true AR031867A1 (es) | 2003-10-08 |
Family
ID=26244953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010104114A AR031867A1 (es) | 2000-08-31 | 2001-08-29 | Compuestos derivados de fenoxibencilamina como ssri, su uso en la preparacion de medicamentos, procedimiento de preparacion del compuesto e intermediarios utiles |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP1313701A1 (es) |
| JP (1) | JP2004507523A (es) |
| KR (1) | KR20030029889A (es) |
| CN (1) | CN1449380A (es) |
| AP (1) | AP2001002265A0 (es) |
| AR (1) | AR031867A1 (es) |
| AU (1) | AU2001278650A1 (es) |
| BG (1) | BG107544A (es) |
| BR (1) | BR0113610A (es) |
| CA (1) | CA2420969A1 (es) |
| CZ (1) | CZ2003467A3 (es) |
| DO (1) | DOP2001000242A (es) |
| DZ (1) | DZ3414A1 (es) |
| EA (1) | EA200300206A1 (es) |
| EE (1) | EE200300084A (es) |
| HN (1) | HN2001000191A (es) |
| HR (1) | HRP20030141A2 (es) |
| HU (1) | HUP0303385A2 (es) |
| IL (1) | IL154343A0 (es) |
| IS (1) | IS6704A (es) |
| MA (1) | MA26945A1 (es) |
| MX (1) | MXPA03001848A (es) |
| NO (1) | NO20030842L (es) |
| NZ (1) | NZ523951A (es) |
| OA (1) | OA12372A (es) |
| PA (1) | PA8526701A1 (es) |
| PE (1) | PE20020346A1 (es) |
| PL (1) | PL360743A1 (es) |
| SK (1) | SK2012003A3 (es) |
| TN (1) | TNSN01131A1 (es) |
| UY (1) | UY26924A1 (es) |
| WO (1) | WO2002018333A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6403597B1 (en) * | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US6436938B1 (en) * | 2001-01-22 | 2002-08-20 | Pfizer Inc. | Combination treatment for depression |
| US20020107244A1 (en) * | 2001-02-02 | 2002-08-08 | Howard Harry R. | Combination treatment for depression |
| US20020183306A1 (en) * | 2001-05-30 | 2002-12-05 | Pfizer Inc. | Combination treatment for sleep disorders including sleep apnea |
| GB0318706D0 (en) * | 2003-08-08 | 2003-09-10 | Pfizer Ltd | Selective serotonin reuptake inhibitors in the treatment of disease |
| AU2005214167B2 (en) | 2004-02-13 | 2008-08-07 | Warner-Lambert Company Llc | Androgen receptor modulators |
| JP2007532621A (ja) | 2004-04-13 | 2007-11-15 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | アンドロゲンモジュレータ |
| EP1740533A1 (en) | 2004-04-22 | 2007-01-10 | Warner-Lambert Company LLC | Androgen modulators |
| WO2006006065A1 (en) | 2004-07-08 | 2006-01-19 | Warner-Lambert Company Llc | Androgen modulators |
| BRPI0514405A (pt) * | 2004-08-18 | 2008-06-10 | Warner Lambert Co | moduladores de androgênio |
| WO2006027684A1 (en) * | 2004-09-10 | 2006-03-16 | Pfizer Products Inc. | Therapeutic diphenyl ether ligands |
| TW200724139A (en) | 2005-05-05 | 2007-07-01 | Warner Lambert Co | Androgen modulators |
| WO2007010350A1 (en) * | 2005-07-19 | 2007-01-25 | Pfizer Products Inc. | Synthesis of therapeutic diphenyl ethers |
| JP4887368B2 (ja) | 2005-10-13 | 2012-02-29 | スミスクライン ビーチャム コーポレーション | 新規ヘテロ環化合物 |
| EP1976495A2 (en) * | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| EP2046747A1 (en) * | 2006-06-29 | 2009-04-15 | Janssen Pharmaceutica N.V. | Substituted aminomethyl benzamide compounds |
| EP2049473A2 (en) * | 2006-06-29 | 2009-04-22 | Janssen Pharmaceutica N.V. | Substituted benzyl amine compounds |
| CN101511775A (zh) | 2006-06-29 | 2009-08-19 | 詹森药业有限公司 | 丁基和丁炔基苄基胺化合物 |
| WO2010059390A1 (en) | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Modulators of serotonin receptor |
| US8642583B2 (en) | 2008-10-30 | 2014-02-04 | Janssen Pharmaceutica Nv | Serotonin receptor modulators |
| KR101043200B1 (ko) * | 2010-11-08 | 2011-06-21 | 성시민 | 호흡용 공기탱크의 공기 충전장치 |
| WO2012102721A1 (en) | 2011-01-27 | 2012-08-02 | Hewlett-Packard Development Company, L.P. | A computing device to connect to a portable device |
| CN113543852A (zh) | 2019-03-06 | 2021-10-22 | 第一三共株式会社 | 吡咯并吡唑衍生物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA923283B (en) * | 1991-05-29 | 1993-01-27 | Akzo Nv | Phenoxyphenyl derivatives |
| KR960703901A (ko) * | 1993-08-19 | 1996-08-31 | 로즈 암스트롱 | 치환된 2(5H)푸라논, 2(5H)티오페논 및 2(5H)피롤론 유도체, 그의 제조 방법 및 엔도텔린 길항제로서의 그의 용도(Substituted 2(5H)Furanone, 2(5H)Thiophenone and 2(5H)Pyrrolone Derivatives, Their Preparation and Their Use as Endothelin antagonists) |
| CZ293595A3 (cs) * | 1995-11-09 | 1999-12-15 | Farmak A. S. | Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích |
| WO1999047497A2 (en) * | 1998-03-13 | 1999-09-23 | Merck Frosst Canada & Co. | Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| CA2364718C (en) * | 1999-02-23 | 2006-07-11 | Pfizer Products Inc. | Monoamine reuptake inhibitors for treatment of cns disorders |
| GB0007884D0 (en) * | 2000-03-31 | 2000-05-17 | Pfizer Ltd | Diphenyl ether compounds useful in therapy |
-
2001
- 2001-08-22 DZ DZ013414A patent/DZ3414A1/fr active
- 2001-08-22 MX MXPA03001848A patent/MXPA03001848A/es active IP Right Grant
- 2001-08-22 EP EP01956734A patent/EP1313701A1/en not_active Withdrawn
- 2001-08-22 HU HU0303385A patent/HUP0303385A2/hu unknown
- 2001-08-22 BR BR0113610-0A patent/BR0113610A/pt not_active IP Right Cessation
- 2001-08-22 WO PCT/IB2001/001521 patent/WO2002018333A1/en not_active Ceased
- 2001-08-22 PL PL36074301A patent/PL360743A1/xx not_active Application Discontinuation
- 2001-08-22 JP JP2002523451A patent/JP2004507523A/ja active Pending
- 2001-08-22 CZ CZ2003467A patent/CZ2003467A3/cs unknown
- 2001-08-22 CA CA002420969A patent/CA2420969A1/en not_active Abandoned
- 2001-08-22 KR KR10-2003-7003011A patent/KR20030029889A/ko not_active Ceased
- 2001-08-22 HR HR20030141A patent/HRP20030141A2/hr not_active Application Discontinuation
- 2001-08-22 AU AU2001278650A patent/AU2001278650A1/en not_active Abandoned
- 2001-08-22 NZ NZ523951A patent/NZ523951A/en unknown
- 2001-08-22 IL IL15434301A patent/IL154343A0/xx unknown
- 2001-08-22 AP APAP/P/2001/002265A patent/AP2001002265A0/en unknown
- 2001-08-22 OA OA1200300056A patent/OA12372A/en unknown
- 2001-08-22 CN CN01814846A patent/CN1449380A/zh active Pending
- 2001-08-22 SK SK201-2003A patent/SK2012003A3/sk unknown
- 2001-08-22 EE EEP200300084A patent/EE200300084A/xx unknown
- 2001-08-22 EA EA200300206A patent/EA200300206A1/ru unknown
- 2001-08-24 PA PA20018526701A patent/PA8526701A1/es unknown
- 2001-08-28 PE PE2001000862A patent/PE20020346A1/es not_active Application Discontinuation
- 2001-08-28 HN HN2001000191A patent/HN2001000191A/es unknown
- 2001-08-29 DO DO2001000242A patent/DOP2001000242A/es unknown
- 2001-08-29 AR ARP010104114A patent/AR031867A1/es unknown
- 2001-08-30 TN TNTNSN01131A patent/TNSN01131A1/fr unknown
- 2001-08-31 UY UY26924A patent/UY26924A1/es not_active Application Discontinuation
-
2003
- 2003-01-30 IS IS6704A patent/IS6704A/is unknown
- 2003-02-07 BG BG107544A patent/BG107544A/bg unknown
- 2003-02-21 MA MA27049A patent/MA26945A1/fr unknown
- 2003-02-24 NO NO20030842A patent/NO20030842L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002018333A1 (en) | 2002-03-07 |
| PE20020346A1 (es) | 2002-05-08 |
| PL360743A1 (en) | 2004-09-20 |
| NO20030842D0 (no) | 2003-02-24 |
| NZ523951A (en) | 2004-09-24 |
| AU2001278650A1 (en) | 2002-03-13 |
| CZ2003467A3 (cs) | 2004-04-14 |
| EA200300206A1 (ru) | 2003-06-26 |
| MXPA03001848A (es) | 2003-06-04 |
| EP1313701A1 (en) | 2003-05-28 |
| IS6704A (is) | 2003-01-30 |
| HRP20030141A2 (en) | 2003-04-30 |
| NO20030842L (no) | 2003-04-28 |
| MA26945A1 (fr) | 2004-12-20 |
| KR20030029889A (ko) | 2003-04-16 |
| PA8526701A1 (es) | 2003-07-28 |
| HN2001000191A (es) | 2002-03-11 |
| BG107544A (bg) | 2003-10-31 |
| UY26924A1 (es) | 2002-03-22 |
| IL154343A0 (en) | 2003-09-17 |
| SK2012003A3 (en) | 2004-06-08 |
| CA2420969A1 (en) | 2002-03-07 |
| EE200300084A (et) | 2005-02-15 |
| BR0113610A (pt) | 2003-06-24 |
| AP2001002265A0 (en) | 2001-09-30 |
| CN1449380A (zh) | 2003-10-15 |
| DOP2001000242A (es) | 2002-05-15 |
| TNSN01131A1 (fr) | 2005-11-10 |
| JP2004507523A (ja) | 2004-03-11 |
| OA12372A (en) | 2006-04-17 |
| HUP0303385A2 (hu) | 2004-03-01 |
| DZ3414A1 (fr) | 2002-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031867A1 (es) | Compuestos derivados de fenoxibencilamina como ssri, su uso en la preparacion de medicamentos, procedimiento de preparacion del compuesto e intermediarios utiles | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| ECSP034563A (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos | |
| AR036114A1 (es) | Tetrahidroimidazol[1,2-a]pirazinas y tetrahidrotriazol[4,3-a]pirazinas como inhibidores de la dipeptidil peptidasa utiles para el tratamiento o la prevencion de la diabetes | |
| NO20053460L (no) | Nye forbindelser med selektiv inhibiterende effekt ved GSK3 | |
| AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
| PA8546601A1 (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
| AR035479A1 (es) | Derivados de eteres biarilicos y sus sales, composiciones farmaceuticas que los comprenden y procedimientos para el tratamiento de trastornos o afecciones | |
| AR063454A1 (es) | Derivados acetamida de diazepan como inhibidores selectivos de 11 beta - hsd1. procesos de obtencion y composiciones farmaceuticas. | |
| MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
| CR8859A (es) | Derivados de piridina | |
| AR036659A1 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| PA8621901A1 (es) | Derivados de sulfonamida para el tratamiento de enfermedades | |
| AR053344A1 (es) | Antagonistas del cgrp,procedimiento para su preparacion,composiciones farmaceuticas que los contienen y usos para el tratamiento de la migrana y otras enfermedades | |
| AR015448A1 (es) | COMBINACIoN DE UN INHIBIDOR DE REABSORCIoN DE 5-HT CON UN ANTAGONISTA O AGONISTA PARCIAL DE H5-HT1B, PROCESO PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA QUE LA CONTIENE, SU USO PARA PREPARAR MEDICAMENTOS PARA TRATAR TRASTORNOS AFECTIVOS Y KIT QUE CONTIENE DICHA COMBINACIoN | |
| AR035818A1 (es) | Fenil-heterociclil-eteres con actividad como inhibidores selectivos de recaptacion de serotonina, composiciones farmaceuticas y su uso en la fabricacion de medicamentos | |
| AR053092A1 (es) | Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis | |
| AR038404A1 (es) | Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye | |
| AR050698A1 (es) | Compuesto de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para la preparacion de dicho compuesto | |
| AR027744A1 (es) | Compuestos de eter difenilico utiles en terapia | |
| AR013503A1 (es) | Una combinacion de un inhibidor de la monoamina oxidasa y un antagonista o agonista parcial selectivo de h5-ht(1b), formulacion farmaceutica, usos ymetodo de preparacion | |
| ECSP088257A (es) | Derivados de amida | |
| PE20060630A1 (es) | Amidas sustituidas de acido tienopirrolcarboxilico, amidas del acido pirrolotiazolcarboxilico y analogos relacionados como inhibidores de la caseina cinasa ie | |
| AR036351A1 (es) | Isoxazolopiridinonas, el uso de las mismas para la fabricacion de un medicamento, composiciones y combinaciones farmaceuticas | |
| ECSP088602A (es) | Compuestos con efectos medicinales debido a la interacción con el receptor de glucocorticoides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |